ArticleExperimental and therapeutic medicine2021
Assessment of three successive treatments of ranibizumab on neovascular macular degeneration by OCT angiography.
Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- CD8+ T cell aging is associated with macular neovascularization area change in neovascular age-related macular degeneration: a prospective cohort study.BMC ophthalmology · 2026Article
- Evaluation of inflammatory hyperreflective foci and plasma EPA as diagnostic and predictive markers for age-related macular degeneration.Frontiers in neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, the efficacy of three consecutive anti-VEGF treatments in patients with neovascular macular degeneration (nAMD) was assessed by optical coherence tomography angiography (OCT-A). A total of 23 eyes with nAMD were treated with intravitreal injections (IVIs) of ranibizumab once a month for three consecutive months. There were eight follow-up time-points: Prior to the initial IVI and on days 1, 3, 7, 14, 30, 60 and 90 after the first IVI. The follow-up examinations consisted of measurements of the best-corrected visual acuity (BCVA), the height of retinal pigmented epithelium detachment (RPED), the greatest linear dimension (GLD), choroidal neovascularization (CNV) flow area, whole retinal thickness and four-quadrant retinal thickness. The results indicated that, when compared with the baseline, the BCVA gradually improved after IVI and improved significantly on days 60 and 90 (P<0.05); the RPED and GLD improved after IVI, with a significant improvement on days 30, 60 and 90 (all, P<0.05); the CNV flow area was gradually shortened in the early stage after IVI but rebounded on day 30, while the difference was statistically significant on day 14 (P<0.05). The temporal retinal thickness was statistically significant on day 30 (P<0.05) and there were statistically significant differences in nasal and inferior retinal thickness on days 14 and 30 compared with prior to IVI (all, P<0.05). The BCVA was positively correlated with the RPED, GLD, CNV flow area and nasal retinal thickness (all, P<0.05). In conclusion, OCT-A may provide an effective reference to guide the evaluation, treatment and monitoring of nAMD. The present study was registered in the Chinese Clinical Trial Registry (CChiTR; no. ChiCTR1900023607; http://www.chictr.org.cn/listbycreater.aspx).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.